Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 4/20 | 0.52 |
| ▸ | CASP1 | P29466 | 3/20 | 0.52 |
| ▸ | CASP9 | P55211 | 3/20 | 0.52 |
| ▸ | CASP7 | P55210 | 2/20 | 0.52 |
| ▸ | CASP6 | P55212 | 2/20 | 0.52 |
| ▸ | CASP8 | Q14790 | 2/20 | 0.52 |
| ▸ | REN | P00797 | 3/20 | 0.50 |
| ▸ | CTSK | P43235 | 5/20 | 0.47 |
| ▸ | CTSB | P07858 | 4/20 | 0.47 |
| ▸ | ELANE | P08246 | 1/20 | 0.47 |
| ▸ | CASP4 | P49662 | 1/20 | 0.44 |
| ▸ | CASP5 | P51878 | 1/20 | 0.44 |
| ▸ | CASP10 | Q92851 | 1/20 | 0.44 |
| ▸ | CTSD | P07339 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21124087 | 1.00 | CASP3 (0.52) | CASP3CASP1CASP9CASP7CASP6 | |
| SCHEMBL24310885 | 0.90 | REN (0.56) | CASP3CASP1CASP9CASP7CASP6 | |
| SCHEMBL31346580 | 0.90 | REN (0.56) | CASP3CASP1CASP9CASP7CASP6 | |
| SCHEMBL24310886 | 0.90 | REN (0.56) | CASP3CASP1CASP9CASP7CASP6 | |
| SCHEMBL15012737 | 0.90 | REN (0.56) | CASP3CASP1CASP9CASP7CASP6 | |
| SCHEMBL28712274 | 0.90 | REN (0.56) | CASP3CASP1CASP9CASP7CASP6 | |
| SCHEMBL18328790 | 0.90 | REN (0.55) | CASP3CASP1CASP9CASP7CASP6 | |
| SCHEMBL20257270 | 0.90 | REN (0.55) | CASP3CASP1CASP9CASP7CASP6 | |
| SCHEMBL23133236 | 0.90 | REN (0.55) | CASP3CASP1CASP9CASP7CASP6 | |
| SCHEMBL21481099 | 0.90 | REN (0.55) | CASP3CASP1CASP9CASP7CASP6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3515559-B1 | COMPOSITIONS AND METHODS FOR IDENTIFICATION, ASSESSMENT, PREVENTION, AND TREATMENT OF AML USING USP10 BIOMARKERS AND MODULATORS | DANA FARBER CANCER INST INC (US) | 2025-05-21 | — | — | EP | disclosed |
| US-11136409-B2 | Compositions and methods for identification, assessment, prevention, and treatment of AML using USP10 biomarkers and modulators | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-10-05 | — | — | US | disclosed |
| US-20190202929-A1 | COMPOSITIONS AND METHODS FOR IDENTIFICATION, ASSESSMENT, PREVENTION, AND TREATMENT OF AML USING USP10 BIOMARKERS AND MODULATORS | DANA-FARBER CANCER INSTITUTE, INC. | 2019-07-04 | — | — | US | disclosed |
| WO-2018057618-A1 | COMPOSITIONS AND METHODS FOR IDENTIFICATION, ASSESSMENT, PREVENTION, AND TREATMENT OF AML USING USP10 BIOMARKERS AND MODULATORS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2018-03-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190202929-A1 | COMPOSITIONS AND METHODS FOR IDENTIFICATION, ASSESSMENT, PREVENTION, AND TREATMENT OF AML USING USP10 BIOMARKERS AND MODULATORS | USP10, MCL1, USP30 | CASP3 526/4885CASP1 1049/4885CASP9 546/4885 |
| US-11136409-B2 | Compositions and methods for identification, assessment, prevention, and treatment of AML using USP10 biomarkers and modulators | USP10, MCL1, USP30 | CASP3 526/4885CASP1 1049/4885CASP9 546/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.